Fig. 6.

Proposed model by which TSA treatment enhances CD1d-mediated antigen presentation to NKT cells. CD1d expression is enhanced following HDACi treatment, due, at least in part, to a dose-dependent increase in CD1d-cell surface expression. Treatment with HDACi results in a decrease in STAT3 as well as STAT3-inducible cytokine secretion by MCL cells. STAT3-inducible cytokines, such as IL-10, inhibit CD1d-mediated antigen presentation. Thus, HDACi treatment restores NKT cell responses through cell-intrinsic and cell-extrinsic mechanisms